
What is claimed is:

1. A compound of formula I



I

or a pharmaceutically acceptable salt, tautomer, isotopolog, or stereoisomer thereof, wherein

R^N is H;

n is 0-4;

each R^1 is independently selected from halogen, CN, and C_{1-3} alkyl;

a is 1 or 2;

R^2 and R^3 are each independently selected from H, and C_{1-3} alkyl, or R^2 and R^3 and the carbon to which they are attached form a substituted or unsubstituted C_{3-6} cycloalkyl;

m is 0-8;


each R^4 is independently substituted or unsubstituted C_{1-3} alkyl, or two R^4 groups, together with the same carbon atom or adjacent carbon atoms to which they are attached, form a substituted or unsubstituted C_{3-6} cycloalkyl, or two R^4 groups together with the non-adjacent carbon atoms to which they are attached form a substituted or unsubstituted 4-7-membered heterocyclyl;

X is N or CR^X;

R^X is hydrogen, halogen, -O(C_{1-6} alkyl) or -(C_{1-9} alkyl);

L is substituted or unsubstituted -O(C_{1-6} alkyl)-, -(C_{1-6} alkyl)O-, -O(C_{1-6} alkyl)O-, or -(C_{1-9} alkyl)-;

V is



wherein

B is N, CH, or CR^B;

each R^B is independently selected from halogen, and substituted or unsubstituted C_{1-6} alkyl;

R^C is halogen, CF_3 or SF_5;

R^5 and R^6 are C_{1-3} alkyl, or R^5 and R^6, together with the carbon atom to which they are attached, form a substituted or unsubstituted C_{3-6} cycloalkyl or a 3-6 membered heterocyclyl; and

b is 0-2.

2. The compound of claim 1, wherein n is 0, a is 1, and R^2 and R^3 are both H.

3. The compound of claim 1 or 2, wherein each R^4 is independently selected from methyl and CF_3.

4. The compound of any one of claims 1 to 3, wherein m is 0, 1, 2, 3 or 4.

5. The compound of any one of claims 1 to 4, wherein X is N or CR^X, where R^X is hydrogen, halogen, -O(C_{1-6} alkyl) or -(C_{1-9} alkyl).


6. The compound of any one of claims 1 to 5, wherein L is substituted or unsubstituted -O$(CH_2)_p$-, -O$(CH_2)_p$O- or -$(CH_2)_p$-, and p is 1-4.

7. The compound of any one of claims 1 to 6, wherein B is CH or N.

8. The compound of any one of claims 1 to 7, wherein R^C is CF_3, Cl or SF_5.

9. The compound of any one of claims 1 to 8, wherein R^5 and R^6 are methyl.

10. The compound of claim 1, having formula II



II

or a pharmaceutically acceptable salt, tautomer, isotopolog, or stereoisomer thereof, wherein

R^N is H;


each R^{4m} is independently hydrogen or substituted or unsubstituted methyl, wherein the substituents, when present are selected from 1 to 5 halo;

X is N or CR^X;

R^x is hydrogen, halogen, -O(C_{1-6} alkyl) or -(C_{1-9} alkyl);

L is substituted or unsubstituted -O(C_{1-3} alkyl)-, -O(C_{1-3} alkyl)O- or -(C_{1-4} alkyl)-;

V is



B is N or CH;

R^C is halogen, CF_3 or SF_5; and

R^5 and R^6 are C_{1-3} alkyl.

11. The compound of claim 1, wherein the compound is selected from Table 1 or a pharmaceutically acceptable salt, tautomer, isotopolog, or stereoisomer thereof.

12. A pharmaceutical composition comprising an effective amount of the compound of any one of claims 1 to 11, or a pharmaceutically acceptable salt, tautomer, isotopologue, or stereoisomer thereof, and a pharmaceutically acceptable carrier, excipient or vehicle.

13. A method for the treatment of an androgen receptor mediated disease, the method comprising administering to a subject in need thereof an effective amount of the compound of any one of claims 1 to 11 or the pharmaceutical composition of claim 12.

14. The method of claim 13, wherein the androgen mediated disease is prostate cancer.

15. The method of claim 14, wherein the prostate cancer is castration resistant prostate cancer (CRPC).